KineMed to Discuss New Applications of Biomarkers for Neurodegenerative Therapeutics at the 7th Annual Neurotech Investing & Partnering Conference

1282

David Fineman, KineMed’s President & CEO joins panel led by Todd Sherer, CEO of the Michael J. Fox Foundation to discuss the latest science behind emerging treatments for neurodegenerative diseases

EMERYVILLE, Calif.–(EON: Enhanced Online News)–KineMed Inc. (www.kinemed.com) announced today that David Fineman, KineMed’s President & CEO, will be a panelist in the session titled “Movement Disorders: Parkinson’s, Huntington’s, and ALS” being held at the 7th annual Neurotech Investing & Partnering Conference at 3:30 PM EST May 21st at the Intercontinental Hotel Boston.

Contributing to the panel’s focus on neurodegenerative conditions such as Parkinson’s disease, ALS and Huntington’s disease, Mr Fineman will discuss and share KineMed’s kinetic biomarker breakthroughs that are accelerating the development of more effective treatments for these difficult-to-treat disorders.

“Biomarkers are reshaping the development and validation of drugs for neurodegenerative diseases,” said Mr. Fineman, “They will additionally be used to create diagnostic tests that will screen, identify disease stage and stratify responders according to the underlying disease pathology, mechanism of action and cellular response to medicines, rather the high-level symptomatic labels that we have traditionally used to describe them – thus enabling the first generation of truly personalized treatments.”

Other panelists will include Bharatt Chowrira, President and CEO, of Addex Pharmaceuticals, Walter Schmidt, CEO of AFFiRiS, and Sjaak Deckers, CEO of Sapiens Steering Brain Stimulation.

About KineMed, Inc.

KineMed, based in California, is a world-leader in the identification and measurement of the dynamic biochemical processes that cause disease. KineMed’s mission is to create better ways to develop medicines and to manage disease. KineMed’s deep biological expertise combined with its core, patented, dynamic proteomics technology platform, accelerates and lowers the cost of diagnostic and therapeutic R&D.

KineMed is constantly seeking to expand its portfolio of collaborations with pharmaceutical, CRO, histopathology, diagnostics, medical instruments and biotechnology partners. Established programs with premier pharmaceutical collaborators address critical challenges facing drug discovery:

  • Focus on causes rather than symptoms: Generating pivotal knowledge for developing blockbuster drugs, by targeting underlying biochemical causes
  • Systems biology approach: Insight into intact living systems, rather than simplified models, ensures that drug effects are understood in their intended biological context
  • Reduce late-stage attrition: Early, decision-relevant metrics of drug activity separate winners from losers and reduce later failures to improve the NPV of R&D spend
  • Powerful assays of disease state: Custom-developed assays create companion diagnostic tests for personalized medicine

About the 7th annual Neurotech Investing & Partnering Conference

The Neurotech Investing and Partnering Conference is a global forum where investors, executives, entrepreneurs, scientists and others involved in the development of new treatments and diagnostics for the brain and nervous system come together to shape the future of their organization and the industry.

This market defining conference features keynotes on the state of the neurotech industry, cutting edge company presentations, leading translational research projects and panel discussions on a comprehensive selection of neurotech topics.

 

Contacts

KineMed Inc.
Lila Taylor, 510-655-6525 ext. 141
Director of Alliance Management
ltaylor@kinemed.com

READ MORE

Source: eon.businesswire.com

Print Friendly, PDF & Email